Home » Stocks » Boston Therapeutics

Boston Therapeutics Inc. (BTHE)

Stock Price: $0.0169 USD 0.0069 (69.00%)
Updated Aug 11, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 1.88M
Revenue (ttm) 16,329
Net Income (ttm) -3.69M
Shares Out 111.13M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $0.0169
Previous Close $0.0100
Change ($) 0.0069
Change (%) 69.00%
Day's Open 0.0169
Day's Range 0.0169 - 0.0169
Day's Volume 21,000
52-Week Range 0.0052 - 0.0332

More Stats

Market Cap 1.88M
Enterprise Value 5.92M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 111.13M
Float 58.54M
EPS (basic) -0.03
EPS (diluted) -0.03
FCF / Share -0.01
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta 0.13
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 115.02
PB Ratio n/a
Revenue 16,329
Operating Income -3.86M
Net Income -3.69M
Free Cash Flow -1.20M
Net Cash -4.04M
Net Cash / Share -0.04
Gross Margin -65.40%
Operating Margin -23,641.47%
Profit Margin -22,622.80%
FCF Margin -7,324.01%
ROA -298.45%
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

Current: $0.0169
Target: 1.80
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-48.53%8.06%-70.31%-0.06%-50.43%-38.29%665.4%927.58%860.75%-
Gross Profit-0.01-0.04-0.02--
Operating Income-3.86-3.28-1.27-1.26-2.10-4.67-4.58-1.46-0.81-0.24
Net Income-3.69-3.60-1.58-3.74-2.49-4.70-4.60-1.48-0.83-0.25
Shares Outstanding11110251.4743.5439.1138.1925.3716.8715.1510.70
Earnings Per Share-0.03-0.04-0.03-0.09-0.06-0.12-0.18-0.09-0.05-0.02
Operating Cash Flow-1.20-0.88-1.28-1.25-1.29-3.47-2.34-0.85-0.39-0.12
Capital Expenditures------0.01-0.01-0.01--
Free Cash Flow-1.20-0.88-1.28-1.25-1.29-3.48-2.35-0.86-0.39-0.12
Cash & Equivalents0.
Total Debt4.052.832.501.420.390.300.300.30--
Net Cash / Debt-4.04-2.82-2.36-0.73-0.35-
Book Value-7.67-4.15-3.88-3.12-0.530.073.350.700.420.53
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Boston Therapeutics Inc.
Country United States
CEO Chi-Heng Cheng

Stock Information

Ticker Symbol BTHE
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: BTHE


Boston Therapeutics, Inc., a pre-clinical and clinical-stage pharmaceutical development company, focuses on the development, manufacture, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements in the United States. Its lead pharmaceutical drug candidates are BTI-320, a non-systemic carbohydrate-based compound that is in Phase IIb clinical trial to reduce post-meal elevation of blood glucose levels in Type 2 diabetic and pre diabetic patients; BTI-410, a peptide injectable compound that has completed Phase Ib clinical trials for type 1 immunosuppression therapy after kidney transplant surgery and type 2 diabetes patients; and IPOXYN, a carbohydrate-based injectable drug to prevent necrosis, or cell death, as well as to treat hypoxic conditions, such as diabetic foot ulcers and other vascular/neurological complications. The company also produces and sells SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement to support healthy post-meal blood glucose. The company was formerly known as Avanyx Therapeutics, Inc. and changed its name to Boston Therapeutics, Inc. in November 2010. Boston Therapeutics, Inc. was founded in 2009 and is headquartered in Lawrence, Massachusetts.